Advertisement

Sjogren’s Syndrome

  • Robert I. Fox

Abstract

The term Sjogren’s syndrome (SS) refers to xeropthalmia and xerostomia due to lymphocytic infiltrates of lacrimal and salivary glands. The condition may exist as a primary entity (primary SS, 1° SS) or in association with other autoimmune disorders such as systemic lupus erythematosus (SLE), dermatomyositis, scleroderma or rheumatoid arthritis (in which the sicca symptoms are termed “secondary” SS, 2° SS). The criteria for diagnosis of primary SS has been controversial. The absence of a uniformly accepted criteria has led to confusion in clinical practice and in the research literature. For example, only 15% of patients that fulfill European (EEC) criteria for SS would fulfill the San Diego criteria. This difference in disease classification leads to difficulty in comparing clinical trials and in elucidating pathogenetic mechanisms, since different patient populations are evaluated. However, a new international criteria has been suggested and will be presented since the final version of this criteria is close to acceptance by rheumatologists and government agencies.

Keywords

Salivary Gland Systemic Lupus Erythematosus Patient Congenital Heart Block Subacute Cutaneous Lupus Erythematosus Sicca Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akbar AN, Salmon M (1997) Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol Today 18: 72–76PubMedCrossRefGoogle Scholar
  2. Alexander EL, Provost TT (1983) Cutaneous manifestations of primary Sjögren’s syndrome: a reflection of vasculitis and association with anti-Ro ( SSA) antibodies. J Invest Dermatol 80: 386–391PubMedCrossRefGoogle Scholar
  3. Alexander E, Provost TT (1987) Sjögren’s syndrome. Association of cutaneous vasculitis with central nervous system disease. Arch Dermatol 123: 801–810PubMedCrossRefGoogle Scholar
  4. Alexander EL, Beall SS, Gordon B, Seines LA, Yannakakis GD, Patronas N, Provost TT, McFarland HF (1988) Magnetic resonance imaging of cerebral lesions in patients with the Sjögren’s syndrome. Annals of Internal Medicine 108: 815–823PubMedGoogle Scholar
  5. Alpert S, Kang HI, Weissman I, Fox RI (1994) Expression of granzyme A in salivary gland biopsies from patients with primary Sjogren’s syndrome. Arthritis Rheum 37: 1046–1054PubMedCrossRefGoogle Scholar
  6. Altmann D, Hogg J, Trowsdale J, Wilkinson D (1989) Cotransfection of ICAM-1 and HLADR reconstittutes human antigen-presenting cell function in mouse L cells. Nature 338: 512–514PubMedCrossRefGoogle Scholar
  7. Andoh Y, Shimura S, Sawai T, Sasaki H, Takishima T, Shirato K (1993) Morphometric analysis of secretory glands in Sjögren’s syndrome. Am Rev Respir Dis 148: 1358–1362PubMedGoogle Scholar
  8. Arnett F (1994) Histocompatibility typing in the rheumatic diseases: diagnostic and prognostic implications. Med Clin NA 20: 371–387Google Scholar
  9. Asherson RA, Fei HM, Staub HL, Khamashta MA, Hughes GRV, Fox RI (1992) Antiphospholipid antibodies and HLA associations in primary Sjögren’s syndrome. Ann Rheum Dis 51: 495–498PubMedCrossRefGoogle Scholar
  10. Bachmann M, Grolz D, Bartsch H, Klein R, Troster H (1997) Analysis of expression of an alternative SS-B cDNA and localization of the encoded N and C terminal peptides. Bioch Bioph Acta 135: 53–63CrossRefGoogle Scholar
  11. Bangert JL, Freeman RG, Sontheimer RD, Gilliam JN (1984) Subacute cutaneous lupus erythematosus and discoid lupus erythematosus. Comparative histopathologic findings. Arch Dermatol 120: 332–337Google Scholar
  12. Bielsa I, Herrero C, Collado A, Cobos A, Palau J, Mascara JM (1994) Histopathologic findings in cutaneous lupus erythematosus. Arch Dermatol 130: 54–58PubMedCrossRefGoogle Scholar
  13. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ (1956) Sjögren’s syndrome: A clinical, pathological and serological study of 62 cases. Medicine (Baltimore) 44: 187–231Google Scholar
  14. Blomgren K, Kawashima S, Saido TC, Karlsson JO, Elmered A, Hagberg H (1995) Fodrin degradation and subcellular distribution of calpains after neonatal rat cerebral hypoxicischemia. Brain Res 684: 143–149PubMedCrossRefGoogle Scholar
  15. Boise L, Gonzalez M, Postema C, Ding L, Lindsten T, Rurka L, Mao X, Nunez G, Thompson C (1993) bd-x, a bd-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 599–608Google Scholar
  16. Breedveld FC (1997) Minocycline in rheumatoid arthritis [editorial; comment]. Arthritis Rheum 40: 794–796PubMedCrossRefGoogle Scholar
  17. Brookes SM, Pandolfino YA, Mitchell TJ, Venables PJ, Maini R (1992) The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol 31: 735–742PubMedCrossRefGoogle Scholar
  18. Buyon JP, Slade SG, Reveille JD, Hamel JC, Chan EK (1994) Autoantibody responses to the “native” 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjogren’s syndrome. J Immunol 152: 3675–3684PubMedGoogle Scholar
  19. Buyon JP (1996) Neonatal lupus. Curr Opin Rheumatol 8: 485–490CrossRefGoogle Scholar
  20. Buyon JP, Tseng CE, Di Donato F, Rashbaum W, Morris A, Chan EK (1997) Cardiac expression of 52beta, an alternative transcript of the congenital heart block-associated 52-kd SS-A/Ro autoantigen, is maximal during fetal development. Arthritis Rheum 40: 655–660PubMedCrossRefGoogle Scholar
  21. Campbell IL (1995) Neuropathogenic actions of cytokines assessed in transgenic mice. Int J Dev Neurosci 13: 275–284PubMedCrossRefGoogle Scholar
  22. Cannon MJ, Pisa P, Fox RI, Cooper NR (1990) Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest 85: 1333–1337PubMedCrossRefGoogle Scholar
  23. Casciola-Rosen L, Anhalt G, Rosen A (1995) DNA dependent protein kinase is one of a subset of autoantigens specifically celaved early during apoptosis. J Exp Med 182: 1625–1634PubMedCrossRefGoogle Scholar
  24. Casiano CA, Martin SI, Green DR, Tan EM (1996a) Selective Cleavage of nuclear autoantigens during CD95 (Fas/Apo-1) mediated T-cell apoptosis. J Exp Med 184: 765–70CrossRefGoogle Scholar
  25. Casiano CA, Tan EM (1996b) Recent developments in the understanding of antinuclear autoantibodies. Int Arch Allergy Immunol 111: 308–313CrossRefGoogle Scholar
  26. Cho CS, Park SH, Min JK, Lee SH, Kim HY (1997) Clinical significances of antibodies to Ro/ SS-A autoantigens and its subtypes in primary Sjogren’s syndrome. Korean J Intern Med 12: 176–181PubMedGoogle Scholar
  27. Cyrus U, Bergeron L, Zho H, Li H, Yuan J (1996) Specific cleavage of a Fodrin during Fas and tumor necrosis facor induced apoptosis is mediated by an ICE/CED-3 protease distinct from the poly ( ADP)-ribose) polymerase protease. J Biol Chem 271: 31277–31282Google Scholar
  28. Daniels T, Fox PC (1992a) Salivary and Oral Components of Sjogren’s Syndrome. Rheum Clinics NA 18: 571–583Google Scholar
  29. Daniels T, Fox PC (1992b) Salivary and oral components of Sjogren’s syndrome. Rheum Dis Clin North Am 18: 571–589PubMedGoogle Scholar
  30. Daniels T, Whitcher JP (1994) Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjogren’s syndrome. Arthritis Rheum 37: 869–877PubMedCrossRefGoogle Scholar
  31. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N (1995) SLElike autoantibodies and Sjogren’s syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 155: 3205–3212PubMedGoogle Scholar
  32. De Keyser F, Hoch SO, Takei M, Dang H, De Keyser H, Rokeach LA, Talal N (1992) Cross-reactivity of the B/B’ subunit of the Sm ribonucleoprotein autoantigen with proline-rich polypeptides. Clin Immunol Immunopathol 62: 285–290PubMedCrossRefGoogle Scholar
  33. Diakowski W, Sikorski AF (1995) Interaction of brain spectrin (fodrin) with phospholipids. Biochemistry 34: 13252–13258PubMedCrossRefGoogle Scholar
  34. Ekstrom J (1989) Autonomic control of salivary secretion. Proc Finn Dent Soc 85: 323–331PubMedGoogle Scholar
  35. Ferraccioli GF, De Vita S, Casatta L, Damato R, Pegoraro I, Bartoli E (1996) Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Clin Exp Rheumatol 14 Suppl 14: S71–80Google Scholar
  36. Ferri C, La Civita L, Longombardo G, Zignego AL, Pasero G (1998) Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus 7: 275–279PubMedCrossRefGoogle Scholar
  37. Fishleder A, Tubbs R, Hesse B, Levin H (1987) Immunoglobulin-gene rearrangement in benign lymphoepithelial lesions. N Engl J Med 316: 1118–1121PubMedCrossRefGoogle Scholar
  38. Flemmig TF, Weinacht S, Rudiger S, Rumetsch M, Jung A, Klaiber B (1996) Adjunctive controlled topical application of tetracycline HC1 in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase-alpha1-proteinase inhibitor in gingival crevicular fluid. J Clin Periodontol 23: 914–921PubMedCrossRefGoogle Scholar
  39. Fox RI (1994) Classification Criteria for Sjogren’s syndrome. Rheumatic Disease Clinics of North America: Current Controversies in Rheumatology 20: 391–403Google Scholar
  40. Fox RI (1995) Sjogren’s syndrome. Curr Opin Rheumatol 7: 409–416PubMedCrossRefGoogle Scholar
  41. Fox RI (1996) Clinical features, pathogenesis, and treatment of Sjogren’s syndrome. Curr Opin Rheumatol 8: 438–445PubMedCrossRefGoogle Scholar
  42. Fox R (1997) Sjogren’s syndrome: Progress and controversies. Med Clin NA 17: 441–534Google Scholar
  43. Fox RI (1998) Sjogren’s syndrome. Pathogenesis and new approaches to therapy. Adv Exp Med Biol 438: 891–902PubMedCrossRefGoogle Scholar
  44. Fox RI (2000) Sjogren’s syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs 9: 2007–2016PubMedCrossRefGoogle Scholar
  45. Fox RI, Adamson III TC, Fong S, Robinson CA, Morgan EL, Robb JA, Howell FV (1983) Lymphocyte phenotype and function of pseudolymphomas associated with Sjögren’s syndrome. J Clin Invest 72: 52–62PubMedCrossRefGoogle Scholar
  46. Fox RI, Carson DA, Chen P, Fong S (1986a) Characterization of a cross reactive idiotype in Sjögren’s syndrome. Scand J Rheumatol 561: 83–88Google Scholar
  47. Fox RI, Chen PP, Carson DA, Fong S (1986b) Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjögren’s syndrome. J Immunol 136: 477–483PubMedGoogle Scholar
  48. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV (1988) Treatment of primary Sjögren’s syndrome with hydroxychloroquine. Amer J Med 85: 62–67PubMedCrossRefGoogle Scholar
  49. Fox RI, Wilson C (1993) Sjögren’s syndrome: The association of interstitial nephritis and keratoconjunctivitis. Diseases affecting the eye and the kidney 266–276Google Scholar
  50. Fox RI, Saito I (1994) Criteria for diagnosis of Sjogren’s syndrome. Rheum Dis Clin North Am 20: 391–407PubMedGoogle Scholar
  51. Fox RI, Kang HI, Ando D, Abrams J, Pisa E (1994a) Cytokine mRNA expression in salivary gland biopsies of Sjogren’s syndrome. J Immunol 152: 5532–5539PubMedGoogle Scholar
  52. Fox R, Kang H, Pisa E (1994b) Cytokine transcription in salivary gland biopsies of Sjögren’s syndrome. J Immunol 151: 132–142Google Scholar
  53. Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 Suppl 1: S31–36CrossRefGoogle Scholar
  54. Freimark B, Fox RI (1987) Detection of Clonally Detected T and B Cells in Salivary Gland Biopsies of Sjogren’s sjogren lacking myoepithelial islands. N E J Med 317: 1158Google Scholar
  55. Friedlaender MH, Fox RI (1998) Punctal occlusion for the treatment of dry eye. Adv Exp Med Biol 438: 1017–1020PubMedCrossRefGoogle Scholar
  56. Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, Mancia D (1994) Peripheral neuropathy associated with primary Sjogren’s syndrome. J Neurol Neurosurg Psychiatry 57: 983–986PubMedCrossRefGoogle Scholar
  57. Grant IA, Hunder GG, Homburger HA, Dyck PJ (1997) Peripheral neuropathy associated with sicca complex. Neurology 48: 855–862PubMedCrossRefGoogle Scholar
  58. Greenwalt R, Golub L, Lavietas B, Ramamurthy N, Gruber B, Laskin R, McNamera T (1994) Tetracyclines inhibit human collagenase in vivo and in vitro. J Rheum 14: 28–32Google Scholar
  59. Griffiths DJ, Venables PJ, Weiss RA, Boyd MT (1997) A novel exogenous retrovirus sequence identified in humans. J Virol 71: 2866–2872PubMedGoogle Scholar
  60. Guggenbuhl P, Jean S, Jego P, Grosbois B, Chales G, Semana G, Lancien G, Veillard E, Pawlotsky Y, Perdriger A (1998) Primary Sjogren’s syndrome: role of the HLA-DRB1 0301-.1501 heterozygotes. J Rheumatol 25: 900–905PubMedGoogle Scholar
  61. Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC (1992) Lymphocytic sialadenitis of Sjögren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 8: 321–323CrossRefGoogle Scholar
  62. Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, Saito I, Noji S, Sugino H, Hayashi Y (1997) Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren’s syndrome. Science 276: 604–607PubMedCrossRefGoogle Scholar
  63. Harley JB, Sestalk AL, Willia LG, Fu SM, Hansen JA, Reichlin M (1989) A model for disease heterogenecity in systemic lupus erythematosus. Arthritis Rheum 32: 826–36PubMedGoogle Scholar
  64. Harper JI (1982) Subacute cutaneous lupus erythematosus (SCLE): a distinct subset of LE. Clin Exp Dermatol 7: 209–212PubMedCrossRefGoogle Scholar
  65. Hayashi Y, Haneji N, Hamano H (1994) Pathogenesis of Sjogren’s syndrome-like autoimmune lesions in MRL/lpr mice. Pathol Int 44: 559–568PubMedCrossRefGoogle Scholar
  66. Hebbar M, Hebbar-Savean K, Hachulla E, Brouillard M, Hatron PY, Devulder B (1995) Participation of cryoglobulinaemia in the severe peripheral neuropathies of primary Sjogren’s syndrome. Ann Med Interne 146: 235–238Google Scholar
  67. Hershberg R, Framson P, Cho D, Lee L, Kovats S, Beitz J, Blum J, Nepom G (1997) Epithelial Cells use two distinct pathways for HLA Class II antigen processing. J Clin Inv 100: 204–215CrossRefGoogle Scholar
  68. Hicks SJ, Carrington SD, Kaswan RL, Stern ME, Corfield AP (1995) Secreted and membrane bound ocular mucins from normal and dry eye dogs. Biochem Soc Trans 23: 53–75Google Scholar
  69. Horsfall AC, Li JM, Maini RN (1996) Placental and fetal cardiac laminin are targets for cross-reacting autoantibodies from mothers of children with congenital heart block. J Autoimmun 9: 561–568PubMedCrossRefGoogle Scholar
  70. Hu Y, Purushotham KR, Wang P, Dawson R, Jr, Humphreys-Beher MG (1994) Down-regulation of beta-adrenergic receptors and signal transduction response in salivary glands of NOD mice. Am J Physiol 266: G433–443PubMedGoogle Scholar
  71. Humphreys-Beher MG (1996) Animal models for autoimmune disease-associated xerostomia and xerophthalmia. Adv Dent Res 10: 73–75PubMedCrossRefGoogle Scholar
  72. Hyde H, Borthwick NJ, Janossy G, Salmon M, Akbar AN (1997) Upregulation of intracellular glutathione by fibroblast-derived factor(s): enhanced survival of activated T cells in the presence of low Bd-2. Blood 89: 2453–2460PubMedGoogle Scholar
  73. Inatomi T, Spurr-Michaud S, Tisdale AS, Gipson IK (1995) Human corneal and conjunctival epithelia express MUC1 mucin. Invest Ophthalmol Vis Sci 36: 1818–1827PubMedGoogle Scholar
  74. Inatomi T, Spurr-Michaud S, Tisdale AS, Zhan Q, Feldman ST, Gipson IK (1996) Expression of secretory mucin genes by human conjunctival epithelia. Invest Ophthalmol Vis Sci 37: 1684–1692PubMedGoogle Scholar
  75. Jabs DA, Burns WH, Prendergast RA (1996) Paradoxic effect of anti-CD4 therapy on lac- rimal gland disease in MRL/Mp-1pr/lpr mice. Invest Ophthalmol Vis Sci 37: 246–250PubMedGoogle Scholar
  76. Janz DM, van der Kraak G (1997) Suppression of apoptosis by gonadotropin, 17betaestradiol, and epidermal growth factor in rainbow trout preovulatory ovarian follicles. Gen Comp Endocrinol 105: 186–193PubMedCrossRefGoogle Scholar
  77. Jean S, Quelvennec E, Alizadeh M, Guggenbuhl P, Birebent B, Perdriger A, Grosbois B, Pawlotsky PY, Semana G (1998) DRB1’ 15 and DRB1’03 extended haplotype interaction in primary Sjogren’s syndrome genetic susceptibility. Clin Exp Rheumatol 16: 725–728PubMedGoogle Scholar
  78. Johnson EO, Skopouli FN, Moutsopoulos HM (2000) Neuroendocrine manifestations in Sjogren’s Syndrome ( In Process Citation]. Rheum Dis Clin North Am 26: 927–949Google Scholar
  79. Jorgensen C, Legouffe MC, Perney P, Coste J, Tissot B, Segarra C, Bologna C, Bourrat L, Combe B, Blanc F, Sany J (1996) Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum 39: 1166–1171PubMedCrossRefGoogle Scholar
  80. Jubert C, Cosnes A, Clerici T, Gaulard P, Andre P, Revuz J, Bagot M (1993) Sjogren’s syndrome and cutaneous B cell lymphoma revealed by anetoderma. Arthritis Rheum 36: 133–134PubMedCrossRefGoogle Scholar
  81. Kang HI, Fei H, Fox RI (1991) Comparison of genetic factors in Chinese, Japanese and Caucasoid patients with Sjöjren’s syndrome. Arthritis and Rheum 34: S41 (supplement)Google Scholar
  82. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89: 888–892PubMedGoogle Scholar
  83. Katayama I, Koyano T, Nishioka K (1994) Prevalence of eyelid dermatitis in primary Sjogren’s syndrome. Int J Dermatol 33: 421–424PubMedCrossRefGoogle Scholar
  84. Koike K, Moriya K, Ishibashi K, Yotsuyanagi H, Shintani Y, Fujie H, Kurokawa K, Matsura Y, Miyamaura T (1997) Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Nat Acad Sci 94: 233–236PubMedCrossRefGoogle Scholar
  85. Kong L, Ogawa N, Nakabayashi T, Liu GT, D’Souza E, McGuff HS, Guerrero D, Talal N, Dang H (1997) Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 40: 87–97PubMedCrossRefGoogle Scholar
  86. Konishi M, Ohosone Y, Matsumura M, Oyamada Y, Yamaguchi K, Kawahara Y, Mimori T, Ikeda Y (1997) Mixed-cryoglobulinemia associated with cutaneous vasculitis and pulmonary symptoms. Intern Med 36: 62–67PubMedCrossRefGoogle Scholar
  87. Konttinen YT, Sorsa T, Hukkanen M, Segerberg M, a et. (1992) Topology of innervation of labial salivary glands by protein gene product 9.5 and synaptophysin immunoreactive nerves in patients with Sjögren’s syndrome. J Rheumatol 19: 30–37PubMedGoogle Scholar
  88. Konttinen YT, Tornwall J, Kemppinen P, Uusitalo H, Sorsa T, Hukkanen M, Polak JM (1996) Neutral endopeptidase (EC 3.4.24.11) in labial salivary glands in healthy controls and in patients with Sjogren’s syndrome. Ann Rheum Dis 55: 513–519PubMedCrossRefGoogle Scholar
  89. Kroemer G (1997) The proto-oncogene bd-2 and its role in regulating apoptosis. Nature Medicine 3: 614–620PubMedCrossRefGoogle Scholar
  90. Kyle R et al. (1971) Benign hyperglobuliemic purpura of Waldenstrom. Medicine (Baltimore) 50: 113–123Google Scholar
  91. Lee LA, Pickrell MB, Reichlin M (1996) Development of complete heart block in an adult patient with Sjogren’s syndrome and anti-Ro/SS-A autoantibodies. Arthritis Rheum 39: 1427–1429PubMedCrossRefGoogle Scholar
  92. Lemp MA (1987) Tear film: new concepts and implications for the management of the dry eye. Trans New Orleans Acad Ophthalmol 35: 53–64PubMedGoogle Scholar
  93. Li DQ, Tseng SC (1995) Three patterns of cytokine expression potentially involved in epithelial-fibroblast interactions of human ocular surface. J Cell Physiol 163: 61–79PubMedCrossRefGoogle Scholar
  94. Li JM, Fan WS, Horsfall AC, Anderson AC, Rigby S, Larsson E, Venables PJ (1996) The expression of human endogenous retrovirus-3 in fetal cardiac tissue and antibodies in congenital heart block. Clin Exp Immunol 104: 388–393PubMedGoogle Scholar
  95. Lu G, Beuerman RW, Zhao S, Sun G, Nguyen DH, Ma S, Kline DG (1997) Tumor necrosis factor-alpha and interleukin-1 induce activation of MAP kinase and SAP kinase in human neuroma fibroblasts. Neurochem Int 30: 401–410PubMedCrossRefGoogle Scholar
  96. Lutz HU, Pfister M, Hornig R (1996) Tissue homeostatic role of naturally occurring anti-band 3 antibodies. Cell Mol Biol (Noisy-le-grand) 42: 995–1005Google Scholar
  97. Magro CM, Crowson AN (1999) The cutaneous pathology associated with seropositivity for antibodies to SSA (Ro): a clinicopathologic study of 23 adult patients without subacute cutaneous lupus erythematosus. Am J Dermatopathol 21: 129–137PubMedCrossRefGoogle Scholar
  98. Main C, Blennerhassett P, Collins SM (1993) Human recombinant interleukin 1 beta suppresses acetylcholine release trom rat myentenc plexus. Gastroenterology 104. 1648–1654.PubMedGoogle Scholar
  99. Manger K, Kalden JR, Manger B (1996) Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 35: 669–675PubMedCrossRefGoogle Scholar
  100. Mariette X, Cazals-Hatem D, Agbalika F, Selimi F, Brunet M, Morinet F, Gluckman E (1996) Absence of cytomegalovirus and Epstein-Barr virus expression in labial salivary glands of patients with chronic graft-versus-host disease. Bone Marrow Transplant 17: 607–610PubMedGoogle Scholar
  101. Martin SJ, O’Brien GA, Nishioka WK, McGahon AJ, Mahboubi A, Saido TC, Green DR (1995) Proteolysis of fodrin (non-erythroid spectrin) during apoptosis. J Biol Chem 270: 6425–6428PubMedCrossRefGoogle Scholar
  102. McCauliffe DP, Faircloth E, Wang L, Hashimoto T, Hoshino Y, Nishikawa T (1996) Similar Ro/SS-A autoantibody epitope and titer responses in annular erythema of Sjogren’s syndrome and subacute cutaneous lupus erythematosus. Arch Dermatol 132: 528–531PubMedCrossRefGoogle Scholar
  103. Merke PA, Polisson RP, Chang Y, Skates SJ, Niles JL (1997) Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 126: 866–873Google Scholar
  104. Merne ME, Syrjanen SM (1996) Detection of Epstein-Barr virus in salivary gland specimens from Sjogren’s syndrome patients. Laryngoscope 106: 1534–1539PubMedCrossRefGoogle Scholar
  105. Miyagawa S, lida T, Fukumoto T, Matsunaga T, Yoshioka A, Shirai T (1995) Anti-Ro/SSAassociated annular erythema in childhood. Br J Dermatol 133: 779–782PubMedCrossRefGoogle Scholar
  106. Mody GM, Cassim B (1998) Rheumatologic manifestations of gastrointestinal disorders. Curr Opin Rheumatol 10: 67–72PubMedCrossRefGoogle Scholar
  107. Mountz JD, Wu J, Cheng J, Zhou T (1994) Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 37: 1415–1420Google Scholar
  108. Navarr M, Cervera R, Font J, Reverter JC, Monteagudo J, Escolar G, Lopez-Soto A, Ordinas A, Ingelmo M (1997) Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 6: 521–526CrossRefGoogle Scholar
  109. Newkirk MM, Shiroky JB, Johnson N, Danoff D, Isenberg DA, Shustik C, Pearson GR (1996) Rheumatic disease patients, prone to Sjogren’s syndrome and/or lymphoma, mount an antibody response to BHRF1, the Epstein-Barr viral homologue of BCL-2. Br J Rheumatol 35: 1075–1081PubMedCrossRefGoogle Scholar
  110. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Solube Fas (Apo-1, CD95) and Soluble Fas ligand in rheumatic diseases. Arth Rheum 40: 1126–1129CrossRefGoogle Scholar
  111. Ochs RL, Stein TW jr, Chan EK, Ruutu M, Tan EM (1996) cDNA cloning and characterization of a novel nucleolar protein. Mol Biol Cell 7: 1015–1024Google Scholar
  112. O’Donnell B, Black AK (1995) Urticarial vasculitis. Int Angiol 14: 166–174PubMedGoogle Scholar
  113. Ogawa N, Dang H, Kong L, Anaya J, Liu G, Talal N (1996) Lymphocyte apoptosis and apoptosis-associated gene expression in Sjogren’s syndrome. Arth Rheum 39: 1875–1886CrossRefGoogle Scholar
  114. Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, Hiroki A, Fujimura T, Yamada A, Itoh K, Nomoto K (1996) Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 39: 1376–1384PubMedCrossRefGoogle Scholar
  115. Pablos JL, Cogolludo V, Pinedo F, Carreira PE (1993) Subcutaneous nodular amyloidosis in Sjögren’s syndrome. Scand J Rheumatol 22: 250–251PubMedCrossRefGoogle Scholar
  116. Perez B, Kraus A, Lopez G, Cifuentes M, Alarcon-Segovia D (1995) Autoimmune thyroid disease in primary Sjogren’s syndrome. Am J Med 99: 480–484PubMedCrossRefGoogle Scholar
  117. Pflugfelder S, Crouse C, Monroy D, Yen M, Rowe M, Atherton S (1993) EBV and the lacrimal gland pathology of Sjogrens syndrome. Am J Path 143: 49–64PubMedGoogle Scholar
  118. Pflugfelder SC, Tseng SC, Yoshino K, Monroy D, Felix C, Reis BL (1997) Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation. Ophthalmology 104: 223–235PubMedGoogle Scholar
  119. Piepenhagen PA, Peters LL, Lux SE, Nelson WJ (1995) Differential expression of Na(+)-K(+)ATPase, ankyrin, fodrin, and E-cadherin along the kidney nephron. Am J Physiol 269: C1417–1432PubMedGoogle Scholar
  120. Pisa EK, Pisa P, Kang HI, Fox RI (1991) High frequence of t(14;18) translocation in salivary gland lymphomas from Sjögren’s syndrome patients. J Exp Med 174: 1245–1250PubMedCrossRefGoogle Scholar
  121. Provost TT, Watson R, Simmons-O’Brien E (1997) Anti-Ro(SS-A) antibody positive Sjogren’s/lupus erythematosus overlap syndrome. Lupus 6: 105–111PubMedCrossRefGoogle Scholar
  122. Ramos-Casals M, Cervera R, Yague J, Garcia-Carrasco M, Trejo O, Jimenez S, Morla RM, Font J, Ingelmo M (1998) Cryoglobulinemia in primary Sjogren’s syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 28: 200–205PubMedCrossRefGoogle Scholar
  123. Reveille J, Wilson R, Provost T, Bias W, Arnett F (1984) Primary Sjögren’s syndrome and other autoimmune diseases in families Ann Intern Med 101: 748Google Scholar
  124. Ricci RM, Meffert JJ, McCollough ML (1998) Primary anetoderma. Cutis 62: 101–103PubMedGoogle Scholar
  125. Rigby S, Cooke S, Weeransing D he, Venables P (1996) Absence of HTLV-1 tax in Sjogren’s syndrome. Arth Rheum 39: 1609–1610CrossRefGoogle Scholar
  126. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG (1996) Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 79: 50–59PubMedCrossRefGoogle Scholar
  127. Robinson C, Yamciuka S, Alford C, Cooper C, Pichardo E, Shah N, Peck M, HumphreyBeher M (1997) Elevated levels of cysteine protease activity in saliva and salivary glands of NOD mouse model for Sjogren’s syndrome. Proc Nat Acad Sci 94: 5767–5771PubMedCrossRefGoogle Scholar
  128. Ruzicka T, Faes J, Bergner T, Peter RU, Braun-Falco O (1991) Annular erythema associated with Sjogren’s syndrome: a variant of systemic lupus erythematosus [see comments]. J Am Acad Dermatol 25: 557–560PubMedCrossRefGoogle Scholar
  129. Saari H, Halinen S, Ganlov K, Sorsa T, Konttinen YT (1997) Salivary mucous glycoprotein MG1 in Sjogren’s syndrome. Clin Chim Acta 259: 83–96PubMedCrossRefGoogle Scholar
  130. Sais G, Admella C, Fantova MJ, Montero JC (1998) Lymphocytic autoimmune hidradenitis, cutaneous leucocytoclastic vasculitis and primary Sjogren’s syndrome. Br J Dermatol 139: 1073–1076PubMedCrossRefGoogle Scholar
  131. Saito I, Servenius B, Compton T, Fox RI (1989) Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjögren’s syndrome. J Exp Med 169: 2191–2198PubMedCrossRefGoogle Scholar
  132. Sall K, Stevenson OD, Mundorf TK, Reis BL (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107: 631–639PubMedCrossRefGoogle Scholar
  133. Sestak AL, Shaver TS, Moser KL, Neas BR, Harley JB (1999) Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree. J Rheumatol 26: 1495–1499PubMedGoogle Scholar
  134. Shattles WG, Brookes SM, Venables PJ, Clark DA, Maini RN (1992) Expression of anitgen reactive with a monoclonal antibody to HTLV-1 P19 in salivary glands in Sjögren’s syndrome. Clin Exp Immunol 89: 46–51PubMedCrossRefGoogle Scholar
  135. Singer DR, Yenning MC, Lockwood CM, Pusey CD (1986) Cryoglobulinaemia: clinical features and response to treatment [published erratum appears in Ann Med Interne (Paris) 1986; 137(5): 436]. Ann Med Interne 137: 251–253Google Scholar
  136. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM (1996) Methotrexate in primary Sjogren’s syndrome. Clin Exp Rheumatol 14: 555–558PubMedGoogle Scholar
  137. Slomiany BL, Murty VL, Piotrowski J, Slomiany A (1996) Salivary mucins in oral mucosal defense. Gen Pharmacol 27: 761–771PubMedCrossRefGoogle Scholar
  138. Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, Lahita R, Maini RN, Reeves W, Reichlin M, Rothfield N, Takasaki Y, van Venrooij WJ, Tan EM (1997) Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis Rheum 40: 413–418PubMedCrossRefGoogle Scholar
  139. Soliven B, Wang N (1995) Tumor necrosis factor-alpha regulates nicotinic responses in mixed cultures of sympathetic neurons and nonneuronal cells. J Neurochem 64: 883–894PubMedCrossRefGoogle Scholar
  140. Spezialetti R, Bluestein HG, Peter JB, Alexander EL (1993) Neuropsychiatric disease in Sjogren’s syndrome: anti-ribosomal P and anti-neuronal antibodies. Am J Med 95: 153–160PubMedCrossRefGoogle Scholar
  141. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC (1998e) A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 438: 643–651PubMedCrossRefGoogle Scholar
  142. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC (1998b) The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17: 584–589PubMedCrossRefGoogle Scholar
  143. Sullivan DA, Wickham LA, Rocha EM, Krenzer KL, Sullivan BD, Steagall R, Cermak JM, Dana MR, Ullman MD, Sato EH, Gao J, Rocha FJ, Ono M, Silveira LA, Lambert RW, Kelleher RS, Tolls DB, Todd I (1999) Androgens and dry eye in Sjogren’s syndrome. Ann NY Acad Sci 876: 312–324PubMedCrossRefGoogle Scholar
  144. Sumida T, Yonaha F, Maeda T, Kita Y, Yoshida S (1994) Expression of sequences homologous to HTLV-1 Tax gene in the labial salivary glands of Japanese patients with Sjogren’s syndrome. Arth Rheum 37: 545–550CrossRefGoogle Scholar
  145. Suzuki M, Nagata S, Hiramatsu K, Takagi I, Ito H, Kitao S, Ito M, Ohta N, Baba S (1996) Elevated levels of soluble Fc epsilon RII/CD23 and antibodies to Epstein-Barr virus in patients with Sjogren’s syndrome. Acta Otolaryngol Suppl (Stockh) 525: 108–112Google Scholar
  146. Tapinos NI, Polihronis M, Moutsopoulos HM (1999) Lymphoma development in Sjogren’s syndrome: novel p53 mutations. Arthritis Rheum 42: 1466–1472PubMedCrossRefGoogle Scholar
  147. Theofilopoulos AN (1995) The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 16: 90–98PubMedCrossRefGoogle Scholar
  148. Tseng CE, Chan EK, Miranda E, Gross M, Di Donato F, Buyon JP (1997) The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/ Ro-SS-B/La complex. Arthritis Rheum 40: 936–944PubMedCrossRefGoogle Scholar
  149. Vazquez J, Fernandez-Shaw C, Marina A, Haas C, Cacabelos R, Valdivieso F (1996) Antibodies to human brain spectrin in Alzheimer’s disease. J Neuroimmunol 68: 39–44PubMedCrossRefGoogle Scholar
  150. Vissink A, Spijkervet FK, Van Nieuw Amerongen A (1996) Aging and saliva: a review of the literature. Spec Care Dentist 16: 95–103PubMedCrossRefGoogle Scholar
  151. Vitali C, Moutsopoulos HM, Bombardieri S (1994) The European Community Study Group on diagnostic criteria for Sjogren’s syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjogren’s syndrome. Ann Rheum Dis 53: 637–647PubMedCrossRefGoogle Scholar
  152. Vitali C, Bombardieri S (1997) The Europian classification criteria for Sjogren’s syndrome (SS): proposal for modification of the rules for classification suggested by the analysis of the receiver operating characteristic (ROCS) curve of the criteria performance. J Rheum 24 (supplement): S18Google Scholar
  153. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, 3rd, Tran-Johnson TK, Muscoplat CC, Trivedi M, Goldlust B, Gallagher SC (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92–01 Study Group. Arch Intern Med 159: 174–181PubMedCrossRefGoogle Scholar
  154. Wagenmann A, Kato T, Yamamoto K, Nishoka K, Burmester G, Hiepe F (1996) Anti-52 kd SSa autoantibodies in different autoimmune diseases preferentially recognize epitopes on the central region of the antigen. J Rheum 23: 462–468PubMedGoogle Scholar
  155. Walcott B, Claros N (1998) Age related decrease in innervation density of the lacrimal gland in mouse models of Sjogren’s syndrome. Adv Exp Med Biol 438: 917–923PubMedCrossRefGoogle Scholar
  156. Watanabe H, Fabricant M, Tisdale AS, Spurr-Michaud SJ, Lindberg K, Gipson IK (1995) Human corneal and conjunctival epithelia produce a mucin-like glycoprotein for the apical surface. Invest Ophthalmol Vis Sci 36: 337–344PubMedGoogle Scholar
  157. Watanabe T, Tsuchida T, Ito Y, Kanda N, Ueda Y, Tamaki K (1997) Annular erythema associ- ated with lupus erythematosus/Sjogren’s syndrome. J Am Acad Dermatol 36: 214–218PubMedCrossRefGoogle Scholar
  158. Wen S, Shimizu N, Yoshiyama H, Mizugaki Y, Shinozaki F, Takada K (1996) Association of Epstein-Barr virus (EBV) with Sjogren’s syndrome: differential EBV expression between epithelial cells and lymphocytes in salivary glands. Am J Pathol 149: 1511–1517PubMedGoogle Scholar
  159. Whitcher JP jr, Gritz DC, Daniels TE (1998) The dry eye: a diagnostic dilemma. Int Ophthalmol Clin 38: 23–37PubMedCrossRefGoogle Scholar
  160. Yocum DE (1996) Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 22: 133–154PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Robert I. Fox

There are no affiliations available

Personalised recommendations